Clinical Trial Update: SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants. [Phase 2]

View source ↗

Summary

Phase 2 trial of SURFAXIN (lucinactant) for the prevention of bronchopulmonary dysplasia in very low birth weight infants was terminated; results were posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchopulmonary Dysplasia
• Respiratory Distress Syndrome

Drugs mentioned

• SURFAXIN (lucinactant)

Snippet

Sponsor: Windtree Therapeutics | Conditions: Respiratory Distress Syndrome, Newborn, Premature Birth | Phase 2 | Status: TERMINATED | Results posted: 2012-06-13